Mereo BioPharma Group plc Annual Net Income (Loss) Attributable to Parent in USD from 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Mereo BioPharma Group plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2022 to 2023.
  • Mereo BioPharma Group plc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$15M, a 130% decline year-over-year.
  • Mereo BioPharma Group plc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$45.3M.
  • Mereo BioPharma Group plc annual Net Income (Loss) Attributable to Parent for 2023 was -$29.5M, a 30.2% increase from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$29.5M +$12.8M +30.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-27
2022 -$42.2M Jan 1, 2022 Dec 31, 2022 10-K 2024-03-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.